LC-MS/MS method for simultaneous Doxorubicin and Baicalein estimation: formulation and pharmacokinetic applications
<b>Aim & objective:</b> Combinatorial delivery of Doxorubicin (DOX) and Baicalein (BAC) has a potential to improve breast cancer treatment by mitigating the cardiotoxicity induced by DOX. The nanoformulation has been optimized and subjected to pharmacokinetic studies using LC-MS/MS.<b>Materials & methods:</b> Nanoformulation bearing DOX and BAC was optimized using quality by design approach and method validation was done following USFDA guidelines.<b>Results:</b> The particle size, PDI and zeta potential of developed nanoformulation were 162.56 ± 2.21 nm, 0.102 ± 0.03 and -16.5 ± 1.21 mV, respectively. DOX-BAC-SNEDDs had a higher AUC<sub>0-t</sub> values of 6128.84 ± 68.71 and 5896.62 ± 99.31 ng/mL/h as compared with DOX-BAC suspension.<b>Conclusion:</b> These findings hold promise for advancing breast cancer treatment and facilitating therapeutic drug monitoring.
Authors
- Manish K. Chourasia (ORCID: https://orcid.org/0000-0002-8318-9325)
- Jiaur R. Gayen (ORCID: https://orcid.org/0000-0001-7703-9307)
- Amrendra Tiwari (ORCID: https://orcid.org/0000-0003-4477-3788)
- Divya Chauhan (ORCID: https://orcid.org/0009-0001-8883-1719)
- Pooja Yadav (ORCID: https://orcid.org/0000-0002-5914-563X)
- Pavan Kumar Yadav (ORCID: https://orcid.org/0000-0002-4092-2320)
- J.V.U.S. Chakradhar
- Naresh Kothuri
- Sonia Verma (ORCID: https://orcid.org/0000-0002-9188-1952)
- Sanjay Singh
- Mitali Sethi
Institutions
- Central Drug Research Institute (IN)
- Academy of Scientific and Innovative Research (IN)
Publication Details
- Journal
- Nanomedicine
- Published
- 2024-09-03
- DOI
- https://doi.org/10.1080/17435889.2024.2390348
- Citations
- 5
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 1.81
Funders
- Department of Science and Technology, Ministry of Science and Technology, India